Geldhof A
ORCID: 0000-0002-6476-5526
· 1 paper in corpus
2019
On August 24, 1998, Remicade® (infliximab), the first tumor necrosis factor-α (TNF) inhibitor, received its initial marketing approval from the US Food and Drug Administration for the treatment of Crohn's disease. Subsequently, Remicade was…